Literature DB >> 7758183

Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance.

S Puri1, B L Baker, D P Dutka, C M Oakley, J M Hughes, J G Cleland.   

Abstract

BACKGROUND: The pulmonary diffusing capacity for carbon monoxide (DLCO) is reduced in chronic heart failure (CHF) and is an independent predictor of peak exercise oxygen uptake. The pathophysiological basis for this remains unknown. The aim of this study was to partition DLCO into its membrane conductance (DM) and capillary blood volume components (Vc) and to assess if alveolar-capillary membrane function correlated with functional status, exercise capacity, and pulmonary vascular resistance. METHODS AND
RESULTS: The classic Roughton and Forster method of measuring single-breath DLCO at varying alveolar oxygen concentrations was used to determine DM and Vc in 15 normal subjects and 50 patients with CHF. All performed symptom-limited maximal bicycle exercise tests with respiratory gas analysis; 15 CHF patients underwent right heart catheterization. DLCO was significantly reduced in CHF patients compared with normal subjects, predominantly because of a reduction in DM (7.0 +/- 2.6 versus 12.9 +/- 3.8 versus 20.0 +/- 6.1 mmol.min-1.kPa-1 in New York Heart Association class III, class II, and normal subjects, respectively, P < .0001), even when the reduction in lung volumes was accounted for by the division of DM by the effective alveolar volume. The Vc component of DLCO was not impaired. DM significantly correlated with maximal exercise oxygen uptake (r = .72, P < .0001) and inversely correlated with pulmonary vascular resistance (r = .65, P < .01) in CHF.
CONCLUSIONS: Reduced alveolar-capillary membrane diffusing capacity is the major component of impaired pulmonary gas transfer in CHF, correlating with maximal exercise capacity and functional status. DM may be a useful marker for the alveolar-capillary barrier damage induced by raised pulmonary capillary pressure.

Entities:  

Mesh:

Year:  1995        PMID: 7758183     DOI: 10.1161/01.cir.91.11.2769

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Origin of symptoms in chronic heart failure.

Authors:  A L Clark
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

Review 2.  Exercise and heart failure: assessment and treatment.

Authors:  Andrew L Clark
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

Review 3.  Neuroendocrine activation after myocardial infarction: causes and consequences.

Authors:  J G Cleland; P J Cowburn; K Morgan
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  Relative contribution of resting haemodynamic profile and lung function to exercise tolerance in male patients with chronic heart failure.

Authors:  P Faggiano; A D'Aloia; A Gualeni; A Giordano
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

5.  Influence of lung volume, fluid and capillary recruitment during positional changes and exercise on thoracic impedance in heart failure.

Authors:  Chul-Ho Kim; Matthew A Fuglestad; Maile L Ceridon Richert; Win K Shen; Bruce D Johnson
Journal:  Respir Physiol Neurobiol       Date:  2014-08-14       Impact factor: 1.931

Review 6.  The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure: fear or reality?

Authors:  R Moskowitz
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 7.  Influence of apnoeic oxygenation in respiratory and circulatory system under general anaesthesia.

Authors:  Alexander Kolettas; Vasilis Grosomanidis; Vasilis Kolettas; Paul Zarogoulidis; Kosmas Tsakiridis; Nikolaos Katsikogiannis; Theodora Tsiouda; Ioanna Kiougioumtzi; Nikolaos Machairiotis; Georgios Drylis; Georgios Kesisis; Thomas Beleveslis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

8.  Does lung diffusion impairment affect exercise capacity in patients with heart failure?

Authors:  P G Agostoni; M Bussotti; P Palermo; M Guazzi
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

Review 9.  Pulmonary Limitations in Heart Failure.

Authors:  Ivan Cundrle; Lyle J Olson; Bruce D Johnson
Journal:  Clin Chest Med       Date:  2019-06       Impact factor: 2.878

Review 10.  Causes and treatment of oedema in patients with heart failure.

Authors:  Andrew L Clark; John G F Cleland
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.